0.132
+0.002
(1.54%)
Jun 17 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | - |
| 52 week | 0.08 - 0.20 |
| Open | - |
| Vol / Avg. | 0.00/16.30M |
| Mkt cap | 1.98M* |
| P/E | - |
| Div/yield | - |
| EPS | 0.00* |
| Shares | 1,498.55M |
| Beta | - |
| Inst. own | - |
| *GBP |
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -557.69% | -398.77% |
| Operating margin | -592.31% | -427.11% |
| EBITD margin | - | -417.81% |
| Return on average assets | -83.10% | -63.20% |
| Return on average equity | -98.07% | -72.42% |
| Employees | 3 | - |
| Carbon Disclosure Rating | - | - |
Address
The Magdalen Centre Robert Robinson Ave, Oxford Science Park
OXFORD, OX4 4GA
United Kingdom - Map
+44-1865-784980 (Phone)
+44-087-01671931 (Fax)
OXFORD, OX4 4GA
United Kingdom - Map
+44-1865-784980 (Phone)
+44-087-01671931 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Physiomics Plc is a United Kingdom-based company engaged in the provision of outsourced systems and computational biology services to pharmaceutical companies. The Company combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the Company�s lead service, is used to optimize the dosing and scheduling of oncology drugs in pre-clinical trials. This optimization improves the efficacy of combinations in pre-clinical xenografts.
Officers and directors
| Mark Philip Chadwick Ph.D | Chief Executive Officer, Executive Director | |
| Christophe D. Chassagnole | Chief Operating Officer, Executive Director | |
| Roger J. Jones | Company Secretary | |
| Paul B Harper PhD | Non-Executive Chairman of the Board |